Short answer
Revolution Medicines Inc (RVMD) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $198M with net income of −$407M.
Q3 2026 key financials · XBRL
- Revenue
- $198M
- Net income
- −$407M
- −33.5% YoY · +36.8% QoQ
- Operating margin
- -188.9%
- EPS (diluted)
- −$1.87
- −16.1% YoY · +39.3% QoQ
Source: XBRL data from the Revolution Medicines Inc (RVMD) Q3 2026 10-Q on SEC EDGAR. USD.
Revolution Medicines Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $197.6M, versus $0 YoY, reflecting RASONQUE launch and channel stocking
- Net loss $407.5M vs $305.2M YoY, operating margin -188.9% vs not applicable
- Best program RASONQUE revenue $197.6M; highest R&D increase zoldonrasib, $78.1M vs $30.9M YoY
- Cash, equivalents and marketable securities $3.7B; operating cash use $1.2B for nine months
- Outlook: R&D and SG&A expected to increase, RASONQUE sales partial-quarter and future cost of sales percentage rising
Risk Factors
- Newly added commercialization risk: RASONQUE U.S. launch in August 2026 created limited commercial-scale manufacturing and marketing experience
- Most material financing update: $250.0 million Term Loan Facility tranche drawn in October 2026, secured by substantially all assets including intellectual property
- Regulatory pricing risk: September 2026 Globe rule would tie Medicare rebates to most-favored-nation pricing, subject to legal challenges
- Near-term market risk: RASONQUE competes with established chemotherapy and targeted therapies with greater commercial infrastructure
- Financial risk: $500.0 million 2033 Notes plus approximately $572.3 million royalty liabilities outstanding at September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.